Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group

DOI Web Site 被引用文献5件
  • Timothy R. Rebbeck
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Tara Friebel
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Henry T. Lynch
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Susan L. Neuhausen
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Laura van ’t Veer
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Judy E. Garber
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Gareth R. Evans
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Steven A. Narod
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Claudine Isaacs
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Ellen Matloff
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Mary B. Daly
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Olufunmilayo I. Olopade
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
  • Barbara L. Weber
    From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...

抄録

<jats:sec><jats:title>Purpose</jats:title><jats:p> Data on the efficacy of bilateral prophylactic mastectomy for breast cancer risk reduction in women with BRCA1 and BRCA2 (BRCA1/2) mutations are limited, despite the clinical use of this risk-management strategy. Thus, we estimated the degree of breast cancer risk reduction after surgery in women who carry these mutations. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Four hundred eighty-three women with disease-associated germline BRCA1/2 mutations were studied for the occurrence of breast cancer. Cases were mutation carriers who underwent bilateral prophylactic mastectomy and who were followed prospectively from the time of their center ascertainment and their surgery, with analyses performed for both follow-up periods. Controls were BRCA1/2 mutation carriers with no history of bilateral prophylactic mastectomy matched to cases on gene, center, and year of birth. Both cases and controls were excluded for previous or concurrent diagnosis of breast cancer. Analyses were adjusted for duration of endogenous ovarian hormone exposure, including age at bilateral prophylactic oophorectomy if applicable. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Breast cancer was diagnosed in two (1.9%) of 105 women who had bilateral prophylactic mastectomy and in 184 (48.7%) of 378 matched controls who did not have the procedure, with a mean follow-up of 6.4 years. Bilateral prophylactic mastectomy reduced the risk of breast cancer by approximately 95% in women with prior or concurrent bilateral prophylactic oophorectomy and by approximately 90% in women with intact ovaries. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Bilateral prophylactic mastectomy reduces the risk of breast cancer in women with BRCA1/2 mutations by approximately 90%. </jats:p></jats:sec>

収録刊行物

被引用文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ